CRC metabolic tumors, classified as consensus molecular subtype 3 (CMS3) (13% of all CRCs), are characterized by chromosome instability (CIN), frequent KRAS mutations (68%), and dysregulation of metabolic pathways (including glucose and fructose) [44,200]. Here, KRAS is linked to colorectal carcinoma.